Facebook
Twitter
LinkedIn
Forward
Evolving Treatment Paradigms for Bladder Cancer: Expert Perspectives on the Latest Data
Join key thought leaders in the world of bladder cancer – Drs. Sam Chang and Shilpa Gupta – as they review the rapidly evolving bladder cancer treatment landscape across the full continuum of care, from emerging data in NMIBC, to novel neoadjuvant and adjuvant regimens in MIBC, to robust paradigmatic changes in locally advanced and mUC, both in the front-line setting and in subsequent lines of therapy. Our experts will also provide the tools necessary for effective therapeutic sequencing of intravesical chemotherapy, BCG, platinum chemotherapy, ICIs, and surgical modalities, as well as adaptive integration of novel combinatorial regimens. Finally, the panel will offer expert insights for anticipating and managing immune-mediated adverse events (imAEs) in patients receiving ICIs.
Target Audience
This activity is designed to meet the educational needs of Urologists and Urologic Oncologists.
Learning Objectives
- Appraise the expanding clinical trial evidentiary base in NMIBC and MIBC, including newly-approved indications, recently-reported data, and current consensus guideline recommendations for treatment.
- Examine the evolving bladder cancer management calculus in non-metastatic disease, with a focus on evidence-based treatment sequencing strategies and/or combinatorial regimens incorporating intravesical chemotherapy, BCG, platinum chemotherapy, immune checkpoint inhibitors, and surgical modalities.
- Design evidence-supported treatment plans for patients with bladder cancer, both in NMIBC and as neoadjuvant/adjuvant therapy in MIBC, by effectively integrating consensus guideline recommendations with patient-centric factors (i.e., performance status, renal function, PD-L1 expression, cytopathology, urinary markers, etc.).
- Identify immune-mediated adverse events (imAEs) that may occur in patients with bladder cancer receiving immune checkpoint inhibitors, either as monotherapy or in combination, and implement adaptive imAE anticipation, recognition, and management strategies.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
Sam S. Chang MD, MBA
Professor, Department of Urology
Patricia and Rodes Hart Professor of Urologic Surgery
Chief Surgical Officer
Chief, Division of Urologic Oncology
Vanderbilt Ingram Cancer Center
Nashville, TN
Shilpa Gupta, MD
Director of the Genitourinary Medical Oncology
Cleveland Clinic
Co-Leader of the Genitourinary Oncology Program
Taussig Cancer Institute
Cleveland, OH
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Planners/Faculty:
Sam S. Chang, MD, MBA-has disclosed that he is a consultant for Janssen, MIR, Pacific Edge, Merck, Pfizer, Prokarium, Photocuret, Urigen, and UroToday.
Shilpa Gupta, MD-has disclosed that she is a member of the Speakers' Bureau for BMS, Gilead, SeaGen, and Janssen. She is a consultant for BMS, EMD Serono, Loxo Oncology, Merck, Natera, Pfizer, and SeaGen. She also has equity in Biontek and Moderna.
Peer Reviewer:
Bashir Al Hussein, MD-has no relevant financial relationships to disclose in relation to the content of this activity.
CEC Staff/Planners:
Susan Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medicine (ACCME)
CEC designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation